https://www.venclextahcp.com/2024-07-11https://www.venclextahcp.com/aml.html2025-04-02https://www.venclextahcp.com/aml/about/moa.html2023-02-23https://www.venclextahcp.com/aml/efficacy/ven-aza/study-design.html2023-03-02https://www.venclextahcp.com/aml/efficacy/ven-aza/patient-demographics.html2025-04-18https://www.venclextahcp.com/aml/efficacy/ven-aza/survival-results.html2023-05-10https://www.venclextahcp.com/aml/efficacy/ven-aza/transfusion-independence.html2023-05-01https://www.venclextahcp.com/aml/efficacy/ven-aza/risk-subgroups.html2023-05-05https://www.venclextahcp.com/aml/efficacy/ven-aza/follow-up-data.html2025-04-02https://www.venclextahcp.com/aml/efficacy/ven-dec/study-design.html2023-03-08https://www.venclextahcp.com/aml/efficacy/ven-ldac/study-design.html2023-02-06https://www.venclextahcp.com/aml/side-effects/side-effects.html2023-02-23https://www.venclextahcp.com/aml/side-effects/ven-aza-safety-profile.html2024-05-20https://www.venclextahcp.com/aml/side-effects/ven-dec-safety-profile.html2023-02-27https://www.venclextahcp.com/aml/side-effects/ven-ldac-safety-profile.html2023-02-27https://www.venclextahcp.com/aml/side-effects/important-safety-information.html2023-02-27https://www.venclextahcp.com/aml/dosing-and-administration/considerations.html2025-04-08https://www.venclextahcp.com/aml/dosing-and-administration/dose-modifications.html2025-04-18https://www.venclextahcp.com/aml/dosing-and-administration/assessment.html2025-04-22https://www.venclextahcp.com/aml/dosing-and-administration/patient-instructions.html2023-03-02https://www.venclextahcp.com/aml/dosing-and-administration/dosing-tool.html2023-04-24https://www.venclextahcp.com/aml/resources/patient-profiles.html2025-08-04https://www.venclextahcp.com/aml/resources/patient-printables.html2023-02-27https://www.venclextahcp.com/aml/resources/helpful-links.html2023-02-23https://www.venclextahcp.com/aml/resources/how-supplied.html2023-03-10https://www.venclextahcp.com/aml/resources/videos.html2024-05-20​​Treatment Management With VENCLEXTA in Newly Diagnosed AMLDr. Erba discusses various treatment considerations to help patients get started on a VENCLEXTA regimen.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/dfac1bfc-bb57-478f-825d-546fa9b71066/1d2f9fa1-ba78-4937-a5f9-38402fcc4e92/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=62984029230011033Transfusion Independence in the VIALE-A TrialDr. Erba discusses transfusion independence and maintenance data from the VIALE-A trial.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/a60e4ffd-1b7f-491b-903f-6d1037150e19/e270e93e-e68c-431d-889d-3fd2ff4a1c44/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6339928716112750Overall Survival in Newly Diagnosed AMLDr. Erba speaks about overall survival rates from the VIALE-A trial.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/ac39c914-f02e-41e5-b466-01921320cb5c/00ce684c-e91e-40f3-a137-5632b04cac3d/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6298403393001755​​Remissions in Newly Diagnosed AMLDr. Erba shares results from the VIALE-A trial regarding overall survival and remissions in newly diagnosed patients with AML.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/eccd452c-0251-4e7b-9fe5-a0fc3d0508e5/cf52460e-18aa-4101-834d-e2040efae5cc/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6298402894001942Efficacy in Newly Diagnosed AMLDr. Erba speaks about key efficacy and safety data from VIALE-A trial.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/0ef0fc95-882e-4919-bdde-95a98928f61f/05e3d22a-1ff8-4dce-a425-ee33c74b72ce/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=62984039350011125https://www.venclextahcp.com/aml/resources/helpful-resources-for-your-practice.html2026-02-18https://www.venclextahcp.com/aml/resources/practice-forms-and-documents.html2023-02-27https://www.venclextahcp.com/aml/financial-support/case-managers.html2026-02-18https://www.venclextahcp.com/aml/financial-support/assistance-options.html2026-02-18https://www.venclextahcp.com/aml/financial-support/eligibility-and-enrollment.html2022-06-01https://www.venclextahcp.com/aml/financial-support/faqs.html2023-03-13https://www.venclextahcp.com/cll.html2025-09-09https://www.venclextahcp.com/cll/about/moa.html2025-01-23https://www.venclextahcp.com/cll/efficacy/ven-g/study-design.html2023-09-07https://www.venclextahcp.com/cll/efficacy/ven-g/progression-free-survival.html2025-01-23https://www.venclextahcp.com/cll/efficacy/ven-g/response-rates.html2023-09-01https://www.venclextahcp.com/cll/efficacy/ven-g/minimal-residual-disease.html2025-01-23https://www.venclextahcp.com/cll/efficacy/ven-g/data.html2025-07-07https://www.venclextahcp.com/cll/efficacy/ven-r/study-design.html2023-09-07https://www.venclextahcp.com/cll/efficacy/ven-r/progression-free-survival.html2025-01-23https://www.venclextahcp.com/cll/efficacy/ven-r/response-rates.html2023-10-12https://www.venclextahcp.com/cll/efficacy/ven-r/minimal-residual-disease.html2023-09-25https://www.venclextahcp.com/cll/efficacy/ven-r/data.html2025-01-23https://www.venclextahcp.com/cll/side-effects/side-effects.html2023-07-21https://www.venclextahcp.com/cll/side-effects/ven-g-safety-profile.html2023-09-21https://www.venclextahcp.com/cll/side-effects/ven-r-safety-profile.html2023-10-12https://www.venclextahcp.com/cll/side-effects/important-safety-information.html2023-08-28https://www.venclextahcp.com/cll/dosing-and-administration/treatment-duration-benefits.html2025-07-07https://www.venclextahcp.com/cll/dosing-and-administration/starting-venclexta.html2025-03-31https://www.venclextahcp.com/cll/dosing-and-administration/assessment.html2023-09-07https://www.venclextahcp.com/cll/dosing-and-administration/ven-g-dosing.html2025-04-18https://www.venclextahcp.com/cll/dosing-and-administration/ven-r-dosing.html2023-12-11https://www.venclextahcp.com/cll/dosing-and-administration/patient-instructions.html2025-01-23https://www.venclextahcp.com/cll/dosing-and-administration/dose-modifications.html2023-07-21https://www.venclextahcp.com/cll/dosing-and-administration/drug-interactions.html2025-01-23https://www.venclextahcp.com/cll/resources/patient-printables.html2023-09-07https://www.venclextahcp.com/cll/resources/helpful-links.html2023-07-21https://www.venclextahcp.com/cll/resources/how-supplied.html2024-10-15https://www.venclextahcp.com/cll/resources/videos.html2025-12-23Navigating comorbiditieshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/02dd8044-acc2-405a-bc6d-d216448d33eb/59b57bc0-0244-4490-b4a4-94cb1bfe8323/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6340443943112764​​Starting VENCLEXTAChristina Patterson, PA-C, explains how to assess, prepare, and initiate VENCLEXTA in patients with previously untreated and R/R CLL.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/475d9bce-c160-431a-87bf-854a5a940caf/475a2683-5117-48fc-a653-2441edf82207/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6311757192112998VENCLEXTA Portraitshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/8fa830e2-0f4b-45d7-9cbf-5f35eea22894/06fba994-3fa6-4da6-8d07-52f8b12289e5/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=634044322711225https://www.venclextahcp.com/cll/resources/helpful-resources-for-your-practice.html2026-02-18https://www.venclextahcp.com/cll/resources/practice-forms-and-documents.html2023-03-02https://www.venclextahcp.com/cll/financial-support/case-managers.html2026-02-18https://www.venclextahcp.com/cll/financial-support/assistance-options.html2026-02-18https://www.venclextahcp.com/cll/financial-support/eligibility-and-enrollment.html2022-06-01https://www.venclextahcp.com/cll/financial-support/faqs.html2023-03-13https://www.venclextahcp.com/contact-a-venclexta-representative.html2023-02-16https://www.venclextahcp.com/register-for-venclexta-updates.html2023-02-16https://www.venclextahcp.com/important-safety-information.html2022-11-18https://www.venclextahcp.com/contact-us.html2023-12-11https://www.venclextahcp.com/privacy-policy.html2023-03-08https://www.venclextahcp.com/wa-consumer-health-data-privacy-policy.html2024-07-15https://www.venclextahcp.com/terms-conditions.html2022-05-10https://www.venclextahcp.com/site-map.html2023-07-06https://www.venclextahcp.com/search-results.html2023-08-17https://www.venclextahcp.com/ven-a.html2026-02-23https://www.venclextahcp.com/ven-a/important-safety-information.html2026-02-18